In situ quantitative measurement of mRNA to predict response to trastuzumab in a cohort of metastatic breast cancer patients.
Maria Vassilakopoulou(Yale University), Amanda Psyrri(National and Kapodistrian University of Athens), Αngelos Koutras(General University Hospital of Patras), E. Razis(Hellenic Cooperative Oncology Group), Jennifer Bordeaux(Lineage Cell Therapeutics (United States)), Dimitrios Pectasides(National and Kapodistrian University of Athens), David L. Rimm(Yale University), Kurt A. Schalper(Yale University), George Fountzilas(Hellenic Cooperative Oncology Group), Vassiliki Kotoula(Aristotle University of Thessaloniki), Veronique Neumeister(Yale University), Nicholas Pavlidis(University of Ioannina), Huan Cheng(Yale University), Helena Linardou(Metropolitan Hospital), Dimosthenis Skarlos(Metropolitan Hospital), Mattheos Bobos(Aristotle University of Thessaloniki)
Cited by 0
Related Papers
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
|Nature|2005|1.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
|JAMA Oncology|2015|834
Programmed death ligand-1 expression in non-small cell lung cancer
|Laboratory Investigation|2013|753